The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review

References

• Mazinani M, Rude BJ. The novel zoonotic Coronavirus disease 2019 (COVID-19) pandemic: health perspective on the outbreak. J Healthc Qual Res. 2021;36(1):47–51. doi:10.1016/j.jhqr.2020.09.004
   PubMedGoogle Scholar
• Luo M, Guo L, Yu M, et al. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public – a systematic review and meta-analysis. Psychiatry Res. 2020;291:113190. doi:10.1016/j.psychres.2020.113190
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, et al. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022;11(6):1511. doi:10.3390/jcm11061511
   PubMed Web of Science ®Google Scholar
• Annunziata MC, Patrì A, Ruggiero A, et al. Cutaneous involvement during COVID-19 pandemic: an emerging sign of infection. J Eur Acad Dermatol Venereol. 2020;34(11):e680–e682. doi:10.1111/jdv.16769
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Annunziata MC, et al. Maskne prevalence and risk factors during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2022;36(9):e678–e680. doi:10.1111/jdv.18248
   PubMed Web of Science ®Google Scholar
• Gisondi P, PIaserico S, Bordin C, et al. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020;34(11):2499–2504. doi:10.1111/jdv.16774
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Marasca C, et al. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328–329. doi:10.1080/09546634.2020.1757605
   PubMed Web of Science ®Google Scholar
• Damiani G, Gironi LC, Grada A, et al. COVID-19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): multi-center, real-life, telemedical, and observational prospective study. Dermatol Ther. 2021;34(2):e14848. doi:10.1111/dth.14848
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Napolitano M, et al. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses. 2020;143:109853. doi:10.1016/j.mehy.2020.109853
   PubMed Web of Science ®Google Scholar
• Campanati A, Martina E, Offidani A. The challenge arising from new knowledge about immune and inflammatory skin diseases: where we are today and where we are going. Biomedicines. 2022;10(5):950. doi:10.3390/biomedicines10050950
   PubMed Web of Science ®Google Scholar
• Scalvenzi M, Villani A, Ruggiero A. Community knowledge about the use, reuse, disinfection and disposal of masks and filtering facepiece respirators: results of a study conducted in a dermatology clinic at the university of Naples in Italy. J Community Health. 2021;46(4):786–793. doi:10.1007/s10900-020-00952-3
   PubMed Web of Science ®Google Scholar
• Zagaria O, Villani A, Ruggiero A, Potestio L, Fabbrocini G, Gallo L. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374. doi:10.1111/dth.15374
   PubMed Web of Science ®Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to ‘cutaneous adverse effects of the available COVID-19 vaccines in India: a questionnaire-based study’ by Bawane J et al. J Eur Acad Dermatol Venereol. 2022;36(11):e863–e864. doi:10.1111/jdv.18341
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Picone V, Fabbrocini G, Martora L, et al. A case of new-onset lichen planus after COVID-19 vaccination. Dermatol Ther. 2022;12(3):801–805. doi:10.1007/s13555-022-00689-y
   Web of Science ®Google Scholar
• Bashshur R, Shannon G, Krupinski E, Grigsby J. The taxonomy of telemedicine. Telemed J E Health. 2011;17(6):484–494.
   PubMed Web of Science ®Google Scholar
• Doraiswamy S, Abraham A, Mamtani R, Cheema S. Use of telehealth during the COVID-19 pandemic: scoping review. J Med Internet Res. 2020;22(12):e24087. doi:10.2196/24087
   PubMed Web of Science ®Google Scholar
• Villani A, Scalvenzi M, Fabbrocini G. Teledermatology: a useful tool to fight COVID-19. J Dermatolog Treat. 2020;31(4):325. doi:10.1080/09546634.2020.1750557
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Annunziata MC, et al. Teledermatology for acne during COVID-19: high patients’ satisfaction in spite of the emergency. J Eur Acad Dermatol Venereol. 2020;34(11):e662–e663. doi:10.1111/jdv.16746
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, et al. Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on ‘can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’ Clin Exp Dermatol. 2022;47(10):1864–1865. doi:10.1111/ced.15291
   PubMed Web of Science ®Google Scholar
• Martora F, Picone V, Fabbrocini G, et al. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42–45. doi:10.1016/j.jdcr.2022.03.008
   PubMedGoogle Scholar
• Ruggiero A, Martora F, Picone V, et al. Paradoxical Hidradenitis Suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455. doi:10.3390/biomedicines10020455
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Bettoli V, Jemec GBE, et al. Anti-COVID-19 measurements for hidradenitis suppurativa patients. Exp Dermatol. 2021;30 Suppl 1(Suppl1):18–22. doi:10.1111/exd.14339
   PubMed Web of Science ®Google Scholar
• Singer HM, Almazan T, Craft N, et al. Using Network Oriented Research Assistant (NORA) technology to compare digital photographic with in-person assessment of acne vulgaris. JAMA Dermatol. 2018;154(2):188–190. doi:10.1001/jamadermatol.2017.5141
   PubMed Web of Science ®Google Scholar
• Frühauf J, Kröck S, Quehenberger F, et al. Mobile teledermatology helping patients control high-need acne: a randomized controlled trial. J Eur Acad Dermatol Venereol. 2015;29(5):919–924. doi:10.1111/jdv.12723
   PubMed Web of Science ®Google Scholar
• Khosravi H, Zhang S, Siripong N, Moorhead A, English JC. Comparing acne follow-up: teledermatology versus outpatient dermatology visits. Dermatol Online J. 2020;26(4). doi:10.5070/D3264048339
   Google Scholar
• Kazi R, Evankovich MR, Liu R, et al. Utilization of asynchronous and synchronous teledermatology in a large health care system during the COVID-19 pandemic. Telemed J E Health. 2021;27(7):771–777.
   PubMed Web of Science ®Google Scholar
• Gu L, Diaz SM, Lipner SR. Retrospective study of acne telemedicine and in-person visits at an academic center during the COVID-19 pandemic. J Cosmet Dermatol. 2022;21(1):36–38. doi:10.1111/jocd.14606
   PubMed Web of Science ®Google Scholar
• Moreno-Ramírez D, Duarte-Ferreras MA, Ojeda-Vila T, et al. Telemedicine management of systemic therapy with isotretinoin of patients with moderate-to-severe acne during the COVID-19 pandemic: a longitudinal prospective feasibility study. J Am Acad Dermatol. 2022;87(5):1186–1189. doi:10.1016/j.jaad.2022.03.004
   PubMed Web of Science ®Google Scholar
• Lee MS, Kassamali B, Shah N, LaChance A, Nambudiri VE. Differences in virtual care utilization for acne by vulnerable populations during the COVID-19 pandemic: a retrospective review. J Am Acad Dermatol. 2021;85(3):718–719. doi:10.1016/j.jaad.2021.05.008
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Fontanella G, et al. Telemedicine and support groups could be used to improve adherence to treatment and health-related quality of life in patients affected by inflammatory skin conditions during the COVID-19 pandemic. Clin Exp Dermatol. 2020;45(6):749. doi:10.1111/ced.14245
   PubMed Web of Science ®Google Scholar
• Villani A, Annunziata MC, Abategiovanni L, et al. Teledermatology for acne patients: how to reduce face-to-face visits during COVID-19 pandemic. J Cosmet Dermatol. 2020;19(8):1828. doi:10.1111/jocd.13519
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Fabbrocini G, et al. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47(10):1863–1864. doi:10.1111/ced.15286
   PubMed Web of Science ®Google Scholar
• Martora F, Ruggiero A, Fabbrocini G, et al. Patient satisfaction with remote dermatology consultations during the COVID-19 pandemic. Comment on ‘A qualitative assessment of patient satisfaction with remote dermatology consultations used during the UK’s first wave of the COVID-19 pandemic in a single, secondary-care dermatology department’. Clin Exp Dermatol. 2022;47(11):2037–2038. doi:10.1111/ced.15326
   PubMed Web of Science ®Google Scholar
• Villani A, Annunziata MC, Megna M, et al. Long-term results of teledermatology for acne patients during COVID-19 pandemic. J Cosmet Dermatol. 2022;21(4):1356–1357. doi:10.1111/jocd.14805
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Marasca C, Fabbrocini G, et al. Teledermatology in the management of hidradenitis suppurativa: should we improve this service? J Cosmet Dermatol. 2022. doi:10.1111/jocd.15292
   Web of Science ®Google Scholar
• Patel NP. Remote consultations for patients with hidradenitis suppurativa during the COVID-19 pandemic: a single-centre experience. Clin Exp Dermatol. 2021;46(6):1079–1081. doi:10.1111/ced.14687
   PubMed Web of Science ®Google Scholar
• Kang N-YC, Hsiao J, Shi V, et al. Remote management of hidradenitis suppurativa in a pandemic era of COVID-19. Int J Dermatol. 2020;59(9):e318–e320. doi:10.1111/ijd.15022
   PubMed Web of Science ®Google Scholar
• Okeke CAV, Shipman WD, Perry JD, et al. Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areas. J Dermatolog Treat. 2022;33(2):1163–1164. doi:10.1080/09546634.2020.1781042
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Battista T, et al. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa’. Clin Exp Dermatol. 2022;47(11):2026–2028. doi:10.1111/ced.15306
   PubMed Web of Science ®Google Scholar
• Pakhchanian H, Raiker R, DeYoung C, Yang S. Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa. Clin Exp Dermatol. 2022;47(6):1186–1188. doi:10.1111/ced.15090
   PubMed Web of Science ®Google Scholar
• Martora F, Martora L, Fabbrocini G, et al. A case of pemphigus vulgaris and Hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa? Skin Appendage Disord. 2022;8(3):265–268. doi:10.1159/000521712
   PubMed Web of Science ®Google Scholar
• Naik HB, Alhusayen R, Frew J, et al. Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: initial findings from the global hidradenitis suppurativa COVID-19 registry. J Am Acad Dermatol. 2022;86(1):249–252. doi:10.1016/j.jaad.2021.09.016
   PubMed Web of Science ®Google Scholar
• Dahy A, El-Qushayri AE, Mahmoud AR, et al. Telemedicine approach for psoriasis management, time for application? A systematic review of published studies. Dermatol Ther. 2020;33(6):e13908. doi:10.1111/dth.13908
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, et al. Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study. Dermatol Ther. 2022;35(1):e15214. doi:10.1111/dth.15214
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Camela E, et al. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;33(2):e13238. doi:10.1111/dth.13238
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;33(5):2560–2564. doi:10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol. 2020;100(3):adv00032. doi:10.2340/00015555-3386
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–2820. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022:1–18. doi:10.1080/14712598.2022.2089020
   Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela E, et al. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis. 2022;12:127–137. doi:10.2147/PTT.S367744
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Mahil SK, Yates M, Yiu ZZN, et al. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol. 2021;35(10):e636–e640. doi:10.1111/jdv.17450
   PubMed Web of Science ®Google Scholar
• Villani A, Megna M, Scalvenzi M, et al. Teledermatology and chronic skin diseases: real life experience in a Southern Italian dermatologic centre. Dermatol Ther. 2020;33(6):e13839. doi:10.1111/dth.13839
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Piaserico S, et al. Preference for telemedicine versus in-person visit among patients with psoriasis receiving biological drugs. Dermatol Ther. 2021;11(4):1333–1343. doi:10.1007/s13555-021-00555-3
   Web of Science ®Google Scholar
• Chat VS, Uppal SK, Kearns DG, et al. Clinical management of psoriasis patients during the COVID-19 pandemic. J Dermatolog Treat. 2022;33(2):1166–1167. doi:10.1080/09546634.2020.1781045
   PubMed Web of Science ®Google Scholar
• Tinio PA, Melendres JM, Chavez CP, et al. Clinical profile and response to treatment of patients with psoriasis seen via teledermatology during the COVID-19 pandemic in the Philippines. JAAD Int. 2022;7:35–37. doi:10.1016/j.jdin.2022.02.001
   PubMedGoogle Scholar
• Ford AR, Gibbons CM, Torres J, et al. Access to dermatological care with an innovative online model for psoriasis management: results from a randomized controlled trial. Telemed J E Health. 2019;25(7):619–627.
   PubMed Web of Science ®Google Scholar
• Balato N, Megna M, Di Costanzo L, Balato A, Ayala F. Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis. Br J Dermatol. 2013;168(1):201–205. doi:10.1111/j.1365-2133.2012.11205.x
   PubMed Web of Science ®Google Scholar
• Frühauf J, Schwantzer G, Ambros-Rudolph CM, et al. Pilot study using teledermatology to manage high-need patients with psoriasis. Arch Dermatol. 2010;146(2):200–201. doi:10.1001/archdermatol.2009.375
   PubMedGoogle Scholar
• Camela E, Potestio L, Fabbrocini G, et al. New frontiers in personalized medicine in psoriasis [published online ahead of print, 2022 Aug 16]. Expert Opin Biol Ther. 2022;2022:1–3.
   Google Scholar
• Camela E, Potestio L, Ruggiero A, et al. Towards personalized medicine in psoriasis: current progress. Psoriasis. 2022;12:231–250. doi:10.2147/PTT.S328460
   PubMed Web of Science ®Google Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122. doi:10.1016/S0140-6736(15)00149-X
   PubMed Web of Science ®Google Scholar
• Napolitano M, Ruggiero A, Fontanella G, et al. New emergent therapies for atopic dermatitis: a review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatol Ther. 2021;34(1):e14475. doi:10.1111/dth.14475
   PubMed Web of Science ®Google Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. doi:10.1159/000370220
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34(6):e15120. doi:10.1111/dth.15120
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242–249. doi:10.1097/ACI.0000000000000837
   PubMed Web of Science ®Google Scholar
• Cantelli M, Martora F, Patruno C, et al. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022;35(4):e15346. doi:10.1111/dth.15346
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi M, Giavina-Bianchi P, Santos AP, et al. Accuracy and efficiency of telemedicine in atopic dermatitis. JAAD Int. 2020;1(2):175–181. doi:10.1016/j.jdin.2020.08.002
   PubMedGoogle Scholar
• Izquierdo-Domínguez A, Rojas-Lechuga MJ, Alobid I, et al. Management of allergic diseases during COVID-19 outbreak. Curr Allergy Asthma Rep. 2021;21(2):8. doi:10.1007/s11882-021-00989-x
   PubMed Web of Science ®Google Scholar
• Ragamin A, de Wijs LEM, Hijnen D-J, et al. Care for children with atopic dermatitis in the Netherlands during the COVID-19 pandemic: lessons from the first wave and implications for the future. J Dermatol. 2021;48(12):1863–1870. doi:10.1111/1346-8138.16130
   PubMed Web of Science ®Google Scholar
• Schmid-Grendelmeier P, Takaoka R, Ahogo KC, et al. Position statement on atopic dermatitis in Sub-Saharan Africa: current status and roadmap. J Eur Acad Dermatol Venereol. 2019;33(11):2019–2028. doi:10.1111/jdv.15972
   PubMed Web of Science ®Google Scholar
• Patruno C, Nisticò SP, Fabbrocini G, et al. COVID-19, quarantine, and atopic dermatitis. Med Hypotheses. 2020;143:109852. doi:10.1016/j.mehy.2020.109852
   PubMed Web of Science ®Google Scholar
• Matricardi PM, Dramburg S, Alvarez-Perea A, et al. The role of mobile health technologies in allergy care: an EAACI position paper. Allergy. 2020;75(2):259–272. doi:10.1111/all.13953
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. The treatment of advanced melanoma: therapeutic update. Int J Mol Sci. 2022;23(12):6388. doi:10.3390/ijms23126388
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fornaro L, et al. The impact of COVID −19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre. Clin Exp Dermatol. 2022;47(11):2024–2025. doi:10.1111/ced.15307
   PubMed Web of Science ®Google Scholar
• Villani A, Scalvenzi M, Fabbrocini G, et al. Effects of COVID-19 pandemic on malignant melanoma diagnosis. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18545
   Web of Science ®Google Scholar
• Andrew TW, Alrawi M, Lovat P. Reduction in skin cancer diagnoses in the UK during the COVID-19 pandemic. Clin Exp Dermatol. 2021;46(1):145–146. doi:10.1111/ced.14411
   PubMed Web of Science ®Google Scholar
• Rashid S, Tsao H. Effect of the COVID-19 pandemic on delayed skin cancer services. Dermatol Clin. 2021;39(4):627–637. doi:10.1016/j.det.2021.05.015
   PubMed Web of Science ®Google Scholar
• Asai Y, Nguyen P, Hanna TP, Picardo M. Impact of the COVID-19 pandemic on skin cancer diagnosis: a population-based study. PLoS One. 2021;16(3):e0248492. doi:10.1371/journal.pone.0248492
   PubMed Web of Science ®Google Scholar
• Earnshaw CH, Hunter HJA, McMullen E, et al. Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic. Br J Dermatol. 2020;183(4):792–794. doi:10.1111/bjd.19267
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fornaro F, et al. Reply to ‘Impact of the French COVID −19 pandemic lockdown on newly diagnosed melanoma delay and severity’ by R. Molinier et al. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18512
   Web of Science ®Google Scholar
• Jobbágy A, Kiss N, Meznerics FA, et al. Emergency use and efficacy of an asynchronous teledermatology system as a novel tool for early diagnosis of skin cancer during the first wave of COVID-19 pandemic. Int J Environ Res Public Health. 2022;19(5):2699. doi:10.3390/ijerph19052699
   PubMed Web of Science ®Google Scholar
• Ziętek M, Nowacki M, Wierzbicki J, et al. The report and analysis concerning the usefulness of basic telemedicine tools in the skin cancer diagnostic screening process during COVID-19 pandemics. Postepy Dermatol Alergol. 2022;39(1):189–194. doi:10.5114/ada.2022.113605
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164–1178. doi:10.1007/s12325-022-02044-1
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic. Dermatol Ther. 2022;35(11):e15786. doi:10.1111/dth.15786
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Megna M, Cinelli E, Gallo L, et al. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619–623. doi:10.1007/s00403-021-02200-7
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, et al. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2282. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Napolitano M, Patruno C, Ruggiero A, et al. Safety of dupilumab in atopic patients during COVID-19 outbreak. J Dermatolog Treat. 2022;33(1):600–601. doi:10.1080/09546634.2020.1771257
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2022;33(2):699–703. doi:10.1080/09546634.2020.1789051
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Marasca C, et al. Skin reaction after SARS-CoV-2 vaccines reply to ‘cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience’. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18531
   Web of Science ®Google Scholar
• Potestio L, Villani A, Fabbrocini G, et al. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? J Cosmet Dermatol. 2022. doi:10.1111/jocd.15331
   Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, et al. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2022. doi:10.1111/jocd.15414
   Web of Science ®Google Scholar
• Wang C-S, Chen -H-H, Liu S-H. Pityriasis rosea-like eruptions following COVID-19 mRNA-1273 vaccination: a case report and literature review. J Formos Med Assoc. 2022;121(5):1003–1007. doi:10.1016/j.jfma.2021.12.028
   PubMed Web of Science ®Google Scholar
• Martora F, Picone V, Fornaro L, et al. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, et al. Reply to ‘development of severe pemphigus vulgaris following SARS-CoV −2 vaccination with BNT162b2’ by Solimani et al. J Eur Acad Dermatol Venereol. 2022;36(10):e750–e751. doi:10.1111/jdv.18302
   PubMed Web of Science ®Google Scholar
• Picone V, Martora F, Fabbrocini G, Marano L. ”Covid arm”: abnormal side effect after moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225
   PubMed Web of Science ®Google Scholar
• Falcinelli F, Lamberti A, Cota C, Rubegni P, Cinotti E. Reply to ‘development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2’ by Solimani F et al. J Eur Acad Dermatol Venereol. 2022;36(12):e976–e978. doi:10.1111/jdv.18398
   PubMed Web of Science ®Google Scholar
• Drago F, Broccolo F, Ciccarese G. Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination. Clin Dermatol. 2022;40(5):SS0738–5. doi:10.1016/j.clindermatol.2022.01.002
   Web of Science ®Google Scholar
• Shah P, Dorrell DN, Feldman SR, et al. The impact of teledermatology during the COVID-19 pandemic. Dermatol Online J. 2021;27(10). doi:10.5070/D3271055615
   Google Scholar
• Bhargava S, Sarkar R, Kroumpouzos G. Mental distress in dermatologists during COVID-19 pandemic: assessment and risk factors in a global, cross-sectional study. Dermatol Ther. 2020;33(6):e14161. doi:10.1111/dth.14161
   PubMed Web of Science ®Google Scholar
• Sendagorta E, Servera G, Nuño A, et al. Direct-to-patient teledermatology during COVID-19 lockdown in a health district in Madrid, Spain: the EVIDE-19 pilot study. Actas Dermosifiliogr. 2021;112(4):345–353. doi:10.1016/j.ad.2020.11.020
   PubMed Web of Science ®Google Scholar
• Deacon DC, Madigan LM. Inpatient teledermatology in the era of COVID-19 and the importance of the complete skin examination. JAAD Case Rep. 2020;6(10):977–978. doi:10.1016/j.jdcr.2020.07.050
   PubMedGoogle Scholar
• Pearlman RL, Le PB, Brodell RT, et al. Evaluation of patient attitudes towards the technical experience of synchronous teledermatology in the era of COVID-19. Arch Dermatol Res. 2021;313(9):769–772. doi:10.1007/s00403-020-02170-2
   PubMed Web of Science ®Google Scholar
• Haque W, Chandy R, Ahmadzada M, et al. Teledermatology after COVID-19: key challenges ahead. Dermatol Online J. 2021;27(4):13030/qt5xr0n44p. doi:10.5070/D3274053151
   PubMedGoogle Scholar
• Choi E, Mak WK, Law JY, et al. Optimizing teledermatology: looking beyond the COVID-19 pandemic. Int J Dermatol. 2021;60(1):119–121. doi:10.1111/ijd.15272
   PubMed Web of Science ®Google Scholar
• Ekeland AG, Bowes A, Flottorp S. Effectiveness of telemedicine: a systematic review of reviews. Int J Med Inform. 2010;79(11):736–771. doi:10.1016/j.ijmedinf.2010.08.006
   PubMed Web of Science ®Google Scholar
• Pasquali P, Sonthalia S, Moreno-Ramirez D, et al. Teledermatology and its current perspective. Indian Dermatol Online J. 2020;11(1):12–20. doi:10.4103/idoj.IDOJ_241_19
   PubMedGoogle Scholar
• Marasca C, Ruggiero A, Annunziata MC, et al. Face the COVID-19 emergency: measures applied in an Italian dermatologic clinic. J Eur Acad Dermatol Venereol. 2020;34(6):e249. doi:10.1111/jdv.16476
   PubMed Web of Science ®Google Scholar
• Gabel CK, Nguyen E, Karmouta R, et al. Use of teledermatology by dermatology hospitalists is effective in the diagnosis and management of inpatient disease. J Am Acad Dermatol. 2021;84(6):1547–1553. doi:10.1016/j.jaad.2020.04.171
   PubMed Web of Science ®Google Scholar
• Altunisik N, Turkmen D, Calikoglu E, et al. Views and experiences of dermatologists in Turkey about teledermatology during the COVID-19 pandemic. J Cosmet Dermatol. 2020;19(10):2460–2463. doi:10.1111/jocd.13677
   PubMed Web of Science ®Google Scholar
• Georgesen C, Karim SA, Liu R, et al. Inpatient eDermatology (teledermatology) can help meet the demand for inpatient skin disease. Telemed J E Health. 2020;26(7):872–878. doi:10.1089/tmj.2019.0147
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, et al. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, et al. Impact of the COVID −19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
   PubMed Web of Science ®Google Scholar